Clinical Trial News and Research

RSS

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.

10 Sep 2009

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe’s proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.

10 Sep 2009

Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.

10 Sep 2009

Cancer Research UK launches a new Cancer Centre at Cardiff

Cardiff today (Thursday) joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

10 Sep 2009

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Affymax, Inc. today announced that it has notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide, by the end of 2009.

10 Sep 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).

10 Sep 2009

Non-invasive CR-2000 Research System to be used in START clinical trial

Hypertension Diagnostics, Inc., today announced that its non-invasive HDI/PulseWave CR-2000 Research System (CR-2000) has been selected for use in the Strategic Timing of AntiRetroviral Treatment (START) substudy on Arterial Elasticity that will examine blood vessel function and cardiovascular risk during HIV infection.

10 Sep 2009

Galapagos starts new clinical trial for GLPG0259

Galapagos NV (Euronext: GLPG) announced today that it has initiated a second Phase I clinical trial for GLPG0259, a novel candidate drug being developed for rheumatoid arthritis (RA).

10 Sep 2009

Oral GLP-1 Analog approved for human clinical trial

Oramed Pharmaceticals, Inc., a developer of oral drug delivery systems, announced today that it has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog.

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

Patient enrollment completed in Phase 2b clinical trial for Pyridorin

NephroGenex, Inc., a privately held drug development company focusing on kidney disease, today announced the completion of patient enrollment in its Phase 2b clinical trial (PYR-210) studying the safety and efficacy of its lead drug candidate Pyridorin (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been randomized.

10 Sep 2009

Federal contract awarded to Children's Hospital of Philadelphia to study use of antibiotics in children

In the largest study of its kind, pediatric researchers at The Children's Hospital of Philadelphia have received a federal contract for a project to determine the most beneficial method of using antibiotics to treat urinary tract infections (UTIs) in children.

10 Sep 2009

Covance expands global footprint with new clinical development offices

Covance Inc. (NYSE: CVD) today announced the opening of new clinical development offices in Sao Paolo, Brazil and Mexico City, Mexico. These offices further expand Covance's global footprint with a comprehensive range of services across Latin America. Earlier this year, Covance announced new offices in Santiago, Chile and Lima, Peru.

10 Sep 2009

American Medical News examines clinical trials outsourcing

American Medical News examines the ethical considerations of outsourcing pharmaceutical clinical trials to developing countries. The article highlights how it is less expensive for a drug company to conduct a trial in India, where it runs about $2,000 to track a patient through a trial, compared to the cost in the U.S., which is "10 times more."

9 Sep 2009

University of California receives $3.5 million grant from NIDA for AIDS vaccine research

The National Institute on Drug Abuse (NIDA) has awarded a $3.5 million grant for AIDS vaccine research to Phillip Berman, professor and chair of biomolecular engineering at the Jack Baskin School of Engineering at the University of California, Santa Cruz.

9 Sep 2009

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

9 Sep 2009

Synexus on track to double its clinical trial capacity in South Africa, opens two new research centres in Pretoria

Manchester-based Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials, celebrated the first phase of its South African expansion programme in Pretoria today.

From AES - Accelerated Enrollment Solutions 9 Sep 2009

Patient enrollment completed in Phase II clinical trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.

9 Sep 2009

Gabapentin improves sleep quality in menopausal women

Gabapentin, a drug initially used to treat seizures, improves sleep quality in menopausal women with hot flashes, University of Rochester Medical Center researchers report online and in the September issue of the Journal of Women's Health.

9 Sep 2009

BioElectronics to file for FDA pre-marketing clearance of its ActiPatch Therapy product

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announces its schedule for filing with the U.S. government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy and RecoveryRx™ products. In these applications BioElectronics will seek over-the-counter clearance of its ActiPatch Therapy product for indications for the treatment of heel and foot pain, and for pain relief relative to general musculoskeletal complaints.

9 Sep 2009

Clinical Trial News and Research

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

Phase III trial demonstrates rapid efficacy of Zelrix in treating acute migraine

Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology

Cancer Research UK launches a new Cancer Centre at Cardiff

Affymax to complete Hematide Phase 3 clinical study by the end of 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Non-invasive CR-2000 Research System to be used in START clinical trial

Galapagos starts new clinical trial for GLPG0259

Oral GLP-1 Analog approved for human clinical trial

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

Patient enrollment completed in Phase 2b clinical trial for Pyridorin

Federal contract awarded to Children's Hospital of Philadelphia to study use of antibiotics in children

Covance expands global footprint with new clinical development offices

American Medical News examines clinical trials outsourcing

University of California receives $3.5 million grant from NIDA for AIDS vaccine research

INSPIRE Phase I/IIa study data to be presented at ICAAC

Synexus on track to double its clinical trial capacity in South Africa, opens two new research centres in Pretoria

Patient enrollment completed in Phase II clinical trial of bavituximab

Gabapentin improves sleep quality in menopausal women

BioElectronics to file for FDA pre-marketing clearance of its ActiPatch Therapy product

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery